Zobrazeno 1 - 10
of 272
pro vyhledávání: '"L Shankar"'
Autor:
Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1273-1285 (2024)
Abstract Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl fumarate (DMF).
Externí odkaz:
https://doaj.org/article/8438206336ce48d6a191208930b85bc7
Autor:
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2199-2203 (2023)
Externí odkaz:
https://doaj.org/article/f752573b25fa4a30838db3262a5c2fdd
Autor:
Lilyana Amezcua, Yang Mao-Draayer, Wendy S. Vargas, Rebecca Farber, Sara Schaefer, Filipe Branco, Sarah M. England, Nicholas Belviso, James B. Lewin, Jason P. Mendoza, Sai L. Shankar, the ENDORSE Study Investigators
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 883-897 (2023)
Abstract Introduction Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in phase 3 DEFINE and CONFIRM trials and in the ENDORSE extension study. Disease activity can differ in younger p
Externí odkaz:
https://doaj.org/article/70917083128f4eb98cbbe4a83c3efa9c
Autor:
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin
Publikováno v:
Neurology and Therapy, Vol 12, Iss 1, Pp 145-159 (2022)
Abstract Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacolog
Externí odkaz:
https://doaj.org/article/f512ef3b56f34173b2ff3a4b8030b0a5
Autor:
Manthey, Bodo, Ram, L. Shankar
In multi-criteria optimization problems, several objective functions have to be optimized. Since the different objective functions are usually in conflict with each other, one cannot consider only one particular solution as the optimal solution. Inst
Externí odkaz:
http://arxiv.org/abs/cs/0606040
Autor:
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L. Arnold, Jelena Drulovic, Elzbieta Jasinska, James D. Bowen, Donald Negroski, Robert T. Naismith, Samuel F. Hunter, Mark Gudesblatt, Hailu Chen, Jennifer Lyons, Sai L. Shankar, Shivani Kapadia, Jason P. Mendoza, Barry A. Singer
Publikováno v:
Advances in Therapy. 39:1810-1831
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77ad905de880352f36f4e160a876434e
https://doi.org/10.1007/s12325-022-02068-7
https://doi.org/10.1007/s12325-022-02068-7
Autor:
Catherine Miller, Sai L Shankar, Jacob Liseno, Brittney Lager, Jason P. Mendoza, James B. Lewin
Publikováno v:
Neurology and Therapy
Introduction Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is approved in the USA for relapsing MS. Following oral administration, DRF is metabolized to monome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1189e18112097cad559f593c8596d7d8
http://europepmc.org/articles/PMC8140165
http://europepmc.org/articles/PMC8140165
Autor:
Jacqueline A Nicholas, Mark Gudesblatt, Meghan Garabedian, Nicholas Belviso, Changyu Shen, Caroline Geremakis, Sai L Shankar, Jason P Mendoza, James B Lewin
Publikováno v:
Multiple sclerosis and related disorders. 63
Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of hospitalization, and healthcare resource utilization (HRU). The infection risk and HRU costs may vary between disease-modifying therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be74e00d1aaa7c2b6df76b6b61ee3f65
https://pubmed.ncbi.nlm.nih.gov/35700674
https://pubmed.ncbi.nlm.nih.gov/35700674
Autor:
Sibyl, Wray, Florian, Then Bergh, Annette, Wundes, Douglas L, Arnold, Jelena, Drulovic, Elzbieta, Jasinska, James D, Bowen, Donald, Negroski, Robert T, Naismith, Samuel F, Hunter, Mark, Gudesblatt, Hailu, Chen, Jennifer, Lyons, Sai L, Shankar, Shivani, Kapadia, Jason P, Mendoza, Barry A, Singer
Publikováno v:
Advances in therapy. 39(4)
Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved gastrointestinal (GI) tolerability and l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd41959579e39a5ea86823fcb638619b
https://pubmed.ncbi.nlm.nih.gov/35211872
https://pubmed.ncbi.nlm.nih.gov/35211872
Autor:
Mark Gudesblatt, Cortnee Roman, Barry A. Singer, Hollie Schmidt, Jessica Thomas, Sai L. Shankar, Jennifer Lyons, Shivani Kapadia
Publikováno v:
Advances in therapy. 39(7)
Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS). Clinical and real-world studies of DRF have demonstrated improved gastrointestinal (GI) tolerability and low ( 1%) GI-related treatment discontinuation versus dimethy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed4eb72752eb1d1b624166738fe4241
https://pubmed.ncbi.nlm.nih.gov/35556227
https://pubmed.ncbi.nlm.nih.gov/35556227